Meeder Advisory Services Inc. Increases Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Meeder Advisory Services Inc. lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,475 shares of the medical equipment provider’s stock after purchasing an additional 288 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Intuitive Surgical were worth $2,185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Modera Wealth Management LLC grew its position in Intuitive Surgical by 2.0% in the third quarter. Modera Wealth Management LLC now owns 1,715 shares of the medical equipment provider’s stock worth $501,000 after acquiring an additional 34 shares in the last quarter. Wellington Management Group LLP lifted its position in Intuitive Surgical by 15.5% during the third quarter. Wellington Management Group LLP now owns 1,097,462 shares of the medical equipment provider’s stock valued at $320,777,000 after acquiring an additional 147,119 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its position in shares of Intuitive Surgical by 9.7% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 7,466 shares of the medical equipment provider’s stock worth $2,182,000 after purchasing an additional 659 shares in the last quarter. Wesbanco Bank Inc. grew its stake in shares of Intuitive Surgical by 53.0% during the third quarter. Wesbanco Bank Inc. now owns 1,146 shares of the medical equipment provider’s stock worth $335,000 after acquiring an additional 397 shares during the last quarter. Finally, Headinvest LLC purchased a new position in shares of Intuitive Surgical in the third quarter worth $28,000. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ISRG. Robert W. Baird reduced their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday, April 19th. BTIG Research upped their price target on Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a report on Monday. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Finally, Morgan Stanley raised their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $419.16.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded down $6.91 during trading hours on Monday, hitting $437.25. The company had a trading volume of 1,573,025 shares, compared to its average volume of 1,506,300. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $449.00. The firm’s fifty day moving average is $418.17 and its 200 day moving average is $391.85. The firm has a market capitalization of $155.09 billion, a price-to-earnings ratio of 78.93, a PEG ratio of 5.74 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period in the previous year, the business earned $1.00 earnings per share. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total transaction of $589,484.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total value of $589,484.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Myriam Curet sold 5,318 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $110,456.68. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock worth $6,927,011 over the last 90 days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.